The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...

To determine the diagnostic accuracy of the results of CSF tests compared to the gold standard PET imaging, the Munich researchers evaluated the data of over 400 patients with suspected Alzheimer's ...

The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...

The first drugs against Alzheimer's disease that are intended to slow down the progression of the condition will soon be authorized in Germany. On November 14, 2024, the EMA granted approval for ...

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue, finds a study led ...

Cardiac arrest (when the heart stops beating) interrupts circulation, causing brain cells to start dying in less than five minutes of the brain going without needed oxygen in the blood. The ...

Background: Cardiac amyloidosis (CA) involves the accumulation of amyloid fibrils in the extracellular cardiac spaces, increasing the extracellular volume (ECV) and correlating with poorer outcomes.

Background: Patients with transthyretin (ATTR) cardiac amyloid infiltration are increasingly diagnosed at earlier disease stages with no heart failure (HF) symptoms and a wide range of cardiac amyloid ...

All patients (n=34) attending the hereditary amyloidosis referral clinic under the joint care of subspecialist cardiac and neurology teams—the Irish Expert Amyloidosis Network—were assessed for ...

Cardiac amyloidosis is becoming increasingly recognized as an etiology for heart failure (HF). Most cases of amyloid cardiomyopathy will fall into one of two categories: light-chain amyloid (AL) ...

Endomyocardial biopsy is the only method by which the presence of cardiac amyloidosis can be directly established in cardiac amyloidosis, but this method is invasive, expensive and not always ...